Next Article in Journal
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Next Article in Special Issue
The c-Met Inhibitor MSC2156119J Effectively Inhibits Tumor Growth in Liver Cancer Models
Previous Article in Journal
Epstein-Barr Virus-Encoded RNAs: Key Molecules in Viral Pathogenesis
Previous Article in Special Issue
Targeting MET Amplification as a New Oncogenic Driver
Article Menu

Export Article

Open AccessReview
Cancers 2014, 6(3), 1631-1669; doi:10.3390/cancers6031631

The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms?

1
Translational Neuro-Oncology Group, Leeds Institute of Cancer and Pathology, University of Leeds, Level 5 Wellcome Trust Brenner Building, St James's Hospital, Leeds LS9 7TF, UK
2
Institute of Research on Cancer and Aging (IRCAN), CNRS-Inserm-UNS UMR 7284, U 1081, Centre A. Lacassagne, 33 Avenue Valombrose, Nice 06189, France
3
Centre Hospitalier Universitaire (CHU), Place Alexis Ricordeau, Nantes 44093, France
4
Inserm UMR892, Centre de Recherche en Cancérologie Nantes-Angers, Institut de Recherche en Santé, Université de Nantes, 8 quai Moncousu, Nantes cedex 44007, France
*
Author to whom correspondence should be addressed.
Received: 30 May 2014 / Revised: 4 August 2014 / Accepted: 4 August 2014 / Published: 12 August 2014
(This article belongs to the Special Issue MET in Cancer)
View Full-Text   |   Download PDF [2256 KB, uploaded 12 August 2014]   |  

Abstract

Met is the receptor of hepatocyte growth factor (HGF), a cytoprotective cytokine. Disturbing the equilibrium between Met and its ligand may lead to inappropriate cell survival, accumulation of genetic abnormalities and eventually, malignancy. Abnormal activation of the HGF/Met axis is established in solid tumours and in chronic haematological malignancies, including myeloma, acute myeloid leukaemia, chronic myelogenous leukaemia (CML), and myeloproliferative neoplasms (MPNs). The molecular mechanisms potentially responsible for the abnormal activation of HGF/Met pathways are described and discussed. Importantly, inCML and in MPNs, the production of HGF is independent of Bcr-Abl and JAK2V617F, the main molecular markers of these diseases. In vitro studies showed that blocking HGF/Met function with neutralizing antibodies or Met inhibitors significantly impairs the growth of JAK2V617F-mutated cells. With personalised medicine and curative treatment in view, blocking activation of HGF/Met could be a useful addition in the treatment of CML and MPNs for those patients with high HGF/MET expression not controlled by current treatments (Bcr-Abl inhibitors in CML; phlebotomy, hydroxurea, JAK inhibitors in MPNs). View Full-Text
Keywords: MET; hepatocyte growth factor (HGF); myeloproliferative neoplasm (MPN); chronic myelogenous leukaemia (CML); MET expression; HGF blood levels; dependence factor; personalised medicine; MET inhibitors; HIF inhibitors MET; hepatocyte growth factor (HGF); myeloproliferative neoplasm (MPN); chronic myelogenous leukaemia (CML); MET expression; HGF blood levels; dependence factor; personalised medicine; MET inhibitors; HIF inhibitors
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Boissinot, M.; Vilaine, M.; Hermouet, S. The Hepatocyte Growth Factor (HGF)/Met Axis: A Neglected Target in the Treatment of Chronic Myeloproliferative Neoplasms? Cancers 2014, 6, 1631-1669.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top